Curing cancer is something we all want to do, but logistical issues remain around translating that into practice, explained Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
In this interview with The American Journal of Managed Care®, Sigrun Hallmeyer, MD, medical oncologist with Advocate Health, addresses logistical holdups in precision medicine that may be preventing all patients who need this care from being able to access it. Among the top issues are inappropriate care and wasteful health care spend.
Transcript
Can you discuss potential policy priorities to increase equitable access to health care?
Curing cancer is, of course, the headline—that's what we're all wanting to do. But where we sort of ail and have an issue with is the logistics of how do you translate that. Precision medicine certainly plays a huge role in that, and health equity plays a huge role in that because access to care is one big problem that we have in this country. Another big problem, which I think is equally large, is that we have a lot of waste within our system. I would say probably a good third of our health care dollar is stuck in our system because we duplicate care, or we have care that is inappropriate, too late or early, wrong, whatever. With all that, we need to become better in becoming efficient and automated.
The utilization of appropriate discussion of precision medicine or personalized care should not be a boutique situation that is only offered to wealthy, highly educated patients who have the resources to come to the oncologist and ask for it. Or conversely, for patients who are seen in higher-level centers of care where the physicians are familiar with the precision medicine approach and have the logistical background that I discussed earlier, where you have all the pieces in place where such tests can actually lead to an impact on their care.
And so what I think would probably be the very best sort of societal approach to equity in care would be that we need to find a way to reflex these type of things. Very simply put, if you have, say, a lung cancer diagnosis, it shouldn't matter if you're diagnosed in South Chicago, or at MD Anderson in Houston, or at Sloan Kettering in New York City. Your specimen should be reflexively tested for targetable mutations and the patient and the physician should be equally enabled to use that information to define a targeted or precision medicine approach to their therapy.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Affirmative Action Repeal Decreases Minority Acceptance and Matriculation in Medical Schools
August 27th 2025Medical school application and matriculation rates decreased for underrepresented racial and ethnic minorities in medicine after the 2023 Supreme Court affirmative action repeal.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
For Better Cancer Outcomes, It’s All About Access
August 21st 2025New drugs aren't the only advances in oncology. Innovation includes collaboration between to remove barriers to remove barriers to care, according to experts who gathered for a session of the Institute for Value-Based Medicine in Arlington, Virginia.
Read More